valsartan has been researched along with Inflammation in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (26.67) | 29.6817 |
| 2010's | 20 (44.44) | 24.3611 |
| 2020's | 13 (28.89) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Y; Liu, C; Yu, M | 1 |
| Cai, L; Cao, Z; Guo, Q; Huang, Q; Li, W; Liu, X; Zeng, R | 1 |
| Akokay, P; Dindaş, F; Doğduş, M; Ekici, M; Erhan, F; Güngör, H; Yılmaz, MB | 1 |
| Ganesh, SK; Hunker, KL; Kanthi, Y; Knight, JS; Kumar, N; Obi, AT; Yalavarthi, S; Zuo, Y | 1 |
| Ahmed, MM; Al-Hoshani, A; Al-Rejaie, SS; Alotaibi, MM; Belali, OM; Belali, TM; Mohany, M | 1 |
| Chai, HT; Chen, CH; Chen, YL; Chiang, JY; Sung, PH; Yang, CC; Yip, HK | 1 |
| Chen, M; He, H; Hong, M; Hu, Q; Jia, Z; Liu, M; Wang, L; Xiao, F; Yang, Y; Zhang, H; Zhang, L | 1 |
| Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H | 1 |
| Acanfora, C; Acanfora, D; Casucci, G; Ciccone, MM; Scicchitano, P | 1 |
| Ferrara, F; La Porta, R; Vitiello, A | 1 |
| Chen, Y; Cui, J; Liu, X; Pan, C; Pang, Z; Ren, Y; Tian, L; Yao, Z; Zhang, L | 1 |
| Fan, Z; Qi, G; Shen, J; Sun, G | 1 |
| Alfadda, AA; Alsalman, N; Bazighifan, A; Gul, R | 1 |
| Janež, A; Janić, M; Kanc, K; Lunder, M; Šabovič, M; Savić, V | 1 |
| Liu, G; Wang, K; Zhang, H; Zhang, J; Zhang, W; Zhou, W | 1 |
| Ge, Q; Hu, ZY; Ren, XM; Ye, P; Zhao, L | 1 |
| Metra, M | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Cheung, AK; Huang, Y; Liu, X; Zhou, G | 1 |
| Chen, H; Hu, X; Jiang, Z; Li, J; Liu, X; Steinhoff, G; Wang, L; Xu, Y; Yu, H; Zhang, Z | 1 |
| Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X | 1 |
| Li, X; Li, Y; Lu, J; Peng, Y; Shen, Q; Wang, Y; Yin, D | 1 |
| Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Nakagawa, T; Ogawa, H; Sueta, D | 1 |
| Cerkovnik, P; Janić, M; Lunder, M; Novaković, S; Prosenc Zmrzljak, U; Šabovič, M | 1 |
| Adi-Bessalem, S; Laraba-Djebari, F; Sifi, A | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Aoyama, I; Bomsztyk, K; Komers, R; Koopmeiners, JS; Naito, M; Schnaper, HW; Shenoy, A | 1 |
| Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Kamal, F; Morioka, T; Oite, T; Piao, H; Yanakieva-Georgieva, N | 1 |
| Brown, NJ; Gamboa, JL; Ikizler, TA; Luther, JM; Pretorius, M; Todd-Tzanetos, DR; Yu, C | 1 |
| Kalantar-Zadeh, K; Zaritsky, JJ | 1 |
| Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z | 1 |
| Alili, R; Blaak, EE; Clément, K; Cleutjens, JP; Diamant, M; Essers, Y; Goossens, GH; Jocken, JW; Moors, CC; van der Zijl, NJ; Venteclef, N | 1 |
| Li, Q; Liu, L; Xiao, J; Xu, Z; Zhao, S | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Danielson, E; Glynn, RJ; Ridker, PM; Rifai, N | 1 |
| Egashira, K; Funakoshi, K; Ihara, Y; Nakano, K; Ohtani, K; Sata, M; Sunagawa, K; Zhao, G | 1 |
| de Gasparo, M | 1 |
| Dagenais, NJ; Dryden, WF; Hanafy, S; Jamali, F | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M | 1 |
| Breu, V; Dechend, R; Fiebeler, A; Ganten, D; Gulba, D; Haller, H; Luft, FC; Luther, T; Mackman, N; Mervaala, EM; Müller, DN; Park, JK; Schmidt, F; Schneider, W; Theuer, J | 1 |
| Akishita, M; Chen, R; de Gasparo, M; Horiuchi, M; Iwai, M; Li, Z; Nakagami, H; Suzuki, J; Wu, L | 1 |
1 review(s) available for valsartan and Inflammation
| Article | Year |
|---|---|
New basic science initiatives with the angiotensin II receptor blocker valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Cell Proliferation; Endothelium, Vascular; Humans; Inflammation; Tetrazoles; Valine; Valsartan; Vasoconstriction; Ventricular Remodeling | 2000 |
7 trial(s) available for valsartan and Inflammation
| Article | Year |
|---|---|
A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arterial Pressure; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Hormone Antagonists; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; Pulmonary Artery; Stroke Volume; Tetrazoles; Treatment Outcome; Troponin T; Valsartan | 2021 |
Low-Dose Fluvastatin and Valsartan Rejuvenate the Arterial Wall Through Telomerase Activity Increase in Middle-Aged Men.
Topics: Arteries; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Inflammation; Leukocytes; Linear Models; Male; Middle Aged; Oxidative Stress; Rejuvenation; Telomerase; Valsartan | 2016 |
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation; CD40 Ligand; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Hemodynamics; Humans; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Ramipril; Renal Dialysis; Renin; Tetrazoles; Valine; Valsartan | 2012 |
Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial.
Topics: Adipocytes; Adipose Tissue; Antihypertensive Agents; Biomarkers; Blood Pressure; Capillaries; Cell Hypoxia; Cell Size; Chemotactic Factors; Double-Blind Method; Fasting; Female; Gene Expression Regulation; Glucose; Humans; Inflammation; Insulin; Lipolysis; Macrophages; Male; Middle Aged; Placebos; Postprandial Period; Tetrazoles; Valine; Valsartan | 2012 |
Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Topics: Aged; Angiotensin II; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Inflammation; Interleukin-1; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; C-Reactive Protein; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Inflammation; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2006 |
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cause of Death; Confidence Intervals; Creatinine; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation; Male; Middle Aged; Norepinephrine; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Treatment Outcome; Troponin T; Valine; Valsartan | 2007 |
37 other study(ies) available for valsartan and Inflammation
| Article | Year |
|---|---|
Effects of calcium dobesilate combined with categlicine and valsartan capsules on inflammation and cellular immunity in patients with diabetic nephropathy.
Topics: Calcium Dobesilate; Capsules; Diabetes Mellitus; Diabetic Nephropathies; Humans; Immunity, Cellular; Inflammation; Valsartan | 2023 |
Valsartan alleviates the blood-brain barrier dysfunction in db/db diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood-Brain Barrier; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells; Inflammation; Male; Mice; Valsartan; Vascular Diseases | 2021 |
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.
Topics: Aminobutyrates; Angiotensins; Animals; Biphenyl Compounds; Cardiotoxicity; Caspase 3; Doxorubicin; Inflammation; Mice; Neprilysin; Oxidative Stress; Receptors, Angiotensin; Valsartan | 2021 |
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism.
Topics: Angiotensin Receptor Antagonists; Cell Adhesion Molecules; Cells, Cultured; COVID-19; Dihydrotestosterone; Endothelium, Vascular; Female; Humans; Inflammation; Male; SARS-CoV-2; Sex Characteristics; Spike Glycoprotein, Coronavirus; Spironolactone; Tumor Necrosis Factor-alpha; Valsartan | 2021 |
LCZ696 Protects against Diabetic Cardiomyopathy-Induced Myocardial Inflammation, ER Stress, and Apoptosis through Inhibiting AGEs/NF-κB and PERK/CHOP Signaling Pathways.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diet, High-Fat; Drug Combinations; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glycation End Products, Advanced; Inflammation; Male; Myocardium; NF-kappa B; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Signal Transduction; Streptozocin; Transcription Factor CHOP; Valsartan | 2022 |
Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Cardio-Renal Syndrome; Cardiovascular Agents; Drug Combinations; Fibrosis; Humans; Inflammation; Kidney; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Simendan; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes.
Topics: Angiotensins; Animals; Glycogen Synthase Kinase 3 beta; Inflammation; Mice; Myocardial Reperfusion Injury; Myocytes, Cardiac; Neprilysin; NF-kappa B; Receptors, Angiotensin; Tetrazoles; Valsartan | 2022 |
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left | 2022 |
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apolipoproteins; Betacoronavirus; Biphenyl Compounds; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Inflammation; Mice; Neprilysin; Pandemics; Plaque, Atherosclerotic; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Tetrazoles; Valsartan | 2020 |
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Biphenyl Compounds; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Combinations; Heart Failure; Homeostasis; Humans; Inflammation; Models, Theoretical; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan; World Health Organization | 2021 |
Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiotonic Agents; Caspases; Cell Line; Cytokines; Disease Models, Animal; Drug Combinations; Heart Injuries; Inflammasomes; Inflammation; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Myocardial Infarction; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphate-Binding Proteins; Pyroptosis; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Valsartan | 2021 |
Comparative beneficial effects of nebivolol and nebivolol/valsartan combination against mitochondrial dysfunction in angiotensin II-induced pathology in H9c2 cardiomyoblasts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Cell Culture Techniques; Drug Combinations; Heart; Hypertension; Inflammation; Mechanistic Target of Rapamycin Complex 1; Mitochondria; Myoblasts, Cardiac; Myocardium; Nebivolol; Organelle Biogenesis; Oxidative Stress; Rats; Reactive Oxygen Species; Valsartan | 2021 |
Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Male; Oxidative Stress; Valsartan | 2017 |
Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Biphenyl Compounds; Chemokine CCL2; Drug Combinations; Drug Therapy, Combination; Gene Expression Regulation; Inflammation; Interleukin-6; Lipids; Matrix Metalloproteinase 8; Mice; Mice, Inbred C57BL; Mice, Knockout; Neprilysin; Plaque, Atherosclerotic; RAW 264.7 Cells; Tetrazoles; Valsartan | 2019 |
LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apoptosis; Biphenyl Compounds; Cell Line; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Inflammation; Male; Mice; Muscle Proteins; Myocardium; Myocytes, Cardiac; Neprilysin; Oxidative Stress; Tetrazoles; Valsartan | 2019 |
August 2019 at a glance: arrhythmogenic cardiomyopathy, biomarkers of inflammation, insulin treatment, initiation of sacubitril/valsartan, and pharmacy-based intervention to increase medication adherence.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmogenic Right Ventricular Dysplasia; Biomarkers; Biphenyl Compounds; Drug Combinations; Humans; Hypoglycemic Agents; Inflammation; Insulin; Interleukin-6; Medication Adherence; Neprilysin; Tetrazoles; Valsartan | 2019 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins | 2014 |
Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair.
Topics: Angiotensin II; Animals; Apoptosis; Bone Marrow Cells; Cell Transplantation; Coculture Techniques; Echocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Inflammation; Leukocytes, Mononuclear; Male; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Stem Cell Transplantation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2013 |
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan blocked alcohol-induced, Toll-like receptor 2 signaling-mediated inflammation in human vascular endothelial cells.
Topics: Angiotensin Receptor Antagonists; Apoptosis; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Ethanol; Humans; In Vitro Techniques; Inflammation; Interleukin-6; NF-kappa B; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Signal Transduction; Tetrazoles; TNF Receptor-Associated Factor 6; Toll-Like Receptor 2; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2014 |
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Blood Pressure; Body Weight; Disease Models, Animal; Inflammation; Interleukin-5; Lipids; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; T-Lymphocyte Subsets; Th2 Cells; Valsartan | 2015 |
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Circadian Rhythm; Cyclic GMP; Drug Combinations; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrosis; Heart; Hypertension; Inflammation; Male; Myocardium; Neprilysin; Oxidative Stress; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Tetrazoles; Valsartan; Vascular Remodeling | 2015 |
Role of angiotensin II and angiotensin type-1 receptor in scorpion venom-induced cardiac and aortic tissue inflammation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Captopril; Catalase; Creatine Kinase, MB Form; Cytokines; Eosinophils; Glutathione; Inflammation; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred Strains; Myocardium; Neutrophils; Oxidation-Reduction; Oxidative Stress; Receptor, Angiotensin, Type 1; Scorpion Venoms; Valsartan | 2017 |
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressure; Cerebral Cortex; Enzyme Activation; Enzyme Inhibitors; Humans; Hydralazine; Hypertension; Inflammation; Male; NADPH Oxidases; Neurons; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Sodium Chloride; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.
Topics: Angiotensin II; Gene Expression Regulation; Glucose; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation; Kidney; Mesangial Cells; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan | 2010 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calpain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Kidney Glomerulus; Male; NF-kappa B; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Streptozocin; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2010 |
The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Inflammation; Male; Ramipril; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2012 |
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Endothelial Cells; Endothelium, Vascular; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; NADPH Oxidases; Oxidative Stress; Pyrrolidines; Receptors, Glucagon; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2012 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biomarkers; Blood Pressure; Blood Vessels; Cell Differentiation; Constriction, Pathologic; Iliac Artery; Imidazoles; Inflammation; Inflammation Mediators; Isoenzymes; Macaca fascicularis; Male; Monocytes; Myocytes, Smooth Muscle; NADPH Oxidases; Oxidative Stress; Rabbits; Recurrence; Renin-Angiotensin System; Stem Cells; Stents; Tetrazoles; Tunica Intima; Valine; Valsartan | 2006 |
Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; C-Reactive Protein; Calcium Channel Blockers; Calcium Channels, L-Type; Drug Interactions; Inflammation; Male; Nitrendipine; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan; Verapamil | 2008 |
Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Coagulation Factors; Blood Pressure; Cell Line; CHO Cells; Coronary Disease; Coronary Vessels; Cricetinae; Extracellular Matrix Proteins; Heart Ventricles; Humans; Inflammation; Integrin alpha4beta1; Integrins; NF-kappa B; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Lymphocyte Homing; RNA, Messenger; Tetrazoles; Thromboplastin; Transcription Factor AP-1; Valine; Valsartan; Vascular Resistance | 2000 |
Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cell Division; Chemokine CCL2; Femoral Artery; Inflammation; Interleukin-1; Interleukin-6; Leukocyte Common Antigens; Leukocytes; Macrophages; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Tumor Necrosis Factor-alpha; Tunica Intima; Valine; Valsartan | 2001 |